08:16 AM EDT, 05/06/2024 (MT Newswires) -- Spectral Medical ( EDTXF ) , which is advancing therapeutic options for sepsis and septic shock, on Monday provided an update on its Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (PMX) in a trial of adults treated for endotoxemia and septic shock.

The company reports that 105 patients were enrolled at end of April, with seven patients signed on in April alone, a record.

Forty-five patients are required to be enrolled to hit the 150 target.

The company says it recently included the University of Virginia as a clinical site, with two more sites pending, subject to finalizing contracting and training.

Spectral is a Phase 3 company seeking U.S. FDA approval for Toraymyxin (PMX), to treat patients with septic shock. PMX is approved for therapeutic use in Japan and Europe.